Shanghai Securities News China SecuritiesNetxun Huiyu Pharmaceutical announced on the evening of the 9th that its subsidiary Seacross Pharma (Europe) Ltd. recently received marketing authorization for the company's product paclitaxel for injection (albumin-bound) approved and issued by the Netherlands Medicines Evaluation Committee, the Irish Health Products Regulatory Authority, the Finnish Medicines Agency, and the Swedish Medicines Agency.
　　Paclitaxel (albumin-bound) for injection is primarily indicated as monotherapy for the treatment of adult patients with metastatic breast cancer whose disease has not improved after first-line treatment of metastatic disease and for whom standard anthracycline-containing regimens are not appropriate; in combination with gemcitabine, it is indicated for the first treatment of adult patients with metastatic pancreatic adenocarcinoma; and in combination with carboplatin, it is indicated for the initial treatment of adult patients with non-small cell lung cancer who are not suitable for potentially curative surgery or radiotherapy.
　　Huiyu Pharmaceuticals stated that following its successful development of paclitaxel (albumin-bound) for injection, it has filed for registration in multiple countries and has received marketing authorization in Denmark, the Netherlands, Ireland, Finland, and Sweden. To date, the company has submitted registration applications in nine countries, including the United Kingdom, Italy, France, and Spain.

https://finance.eastmoney.com/a/202510103530226992.html